Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Endothelial cell-specific progerin expression does not cause cardiovascular alterations and premature death.

  • Benedicto, Ignacio
  • Hamczyk, Magda R
  • Nevado, Rosa M
  • Barettino, Ana
  • Carmona, Rosa M
  • Espinós-Estévez, Carla
  • Gonzalo, Pilar
  • de la Fuente-Pérez, Miguel
  • Andrés-Manzano, María J
  • González-Gómez, Cristina
  • Dorado, Beatriz
  • Andrés, Vicente
Hutchinson-Gilford progeria syndrome (HGPS) is a rare genetic disorder caused by a mutation in the LMNA gene that provokes the synthesis of progerin, a mutant version of the nuclear protein lamin A that accelerates aging and precipitates death. The most clinically relevant feature of HGPS is the development of cardiac anomalies and severe vascular alterations, including massive loss of vascular smooth muscle cells, increased fibrosis, and generalized atherosclerosis. However, it is unclear if progerin expression in endothelial cells (ECs) causes the cardiovascular manifestations of HGPS. To tackle this question, we generated atherosclerosis-free mice (LmnaCdh5-CreERT2) and atheroprone mice (ApoeLmnaCdh5-CreERT2) with EC-specific progerin expression. Like progerin-free controls, LmnaCdh5-CreERT2 mice did not develop heart fibrosis or cardiac electrical and functional alterations, and had normal vascular structure, body weight, and lifespan. Similarly, atheroprone ApoeLmnaCdh5-CreERT2 mice showed no alteration in body weight or lifespan versus ApoeLmna controls and did not develop vascular alterations or aggravated atherosclerosis. Our results indicate that progerin expression in ECs is not sufficient to cause the cardiovascular phenotype and premature death associated with progeria.
Repisalud
Publication Artículo científico (JournalArticle)

Endothelial YAP/TAZ activation promotes atherosclerosis in a mouse model of Hutchinson-Gilford progeria syndrome.

  • Barettino, Ana
  • González-Gómez, Cristina
  • Gonzalo, Pilar
  • Andrés-Manzano, María J
  • Guerrero, Carlos R
  • Espinosa, Francisco M
  • Carmona, Rosa M
  • Blanco, Yaazan
  • Dorado, Beatriz
  • Torroja, Carlos
  • Sánchez-Cabo, Fátima
  • Quintas, Ana
  • Benguría, Alberto
  • Dopazo, Ana
  • García, Ricardo
  • Benedicto, Ignacio
  • Andrés, Vicente
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare disease caused by the expression of progerin, an aberrant protein produced by a point mutation in the LMNA gene. HGPS patients show accelerated aging and die prematurely mainly from complications of atherosclerosis such as myocardial infarction, heart failure, or stroke. However, the mechanisms underlying HGPS vascular pathology remain ill-defined. We used single-cell RNA sequencing to characterize the aorta in progerin-expressing LmnaG609G/G609G mice and wild-type controls, with a special focus on endothelial cells (ECs). HGPS ECs showed gene expression changes associated with extracellular matrix alterations, increased leukocyte extravasation, and activation of the yes-associated protein 1/transcriptional activator with PDZ-binding domain (YAP/TAZ) mechanosensing pathway, all validated by different techniques. Atomic force microscopy experiments demonstrated stiffer subendothelial extracellular matrix in progeroid aortae, and ultrasound assessment of live HGPS mice revealed disturbed aortic blood flow, both key inducers of the YAP/TAZ pathway in ECs. YAP/TAZ inhibition with verteporfin reduced leukocyte accumulation in the aortic intimal layer and decreased atherosclerosis burden in progeroid mice. Our findings identify endothelial YAP/TAZ signaling as a key mechanism of HGPS vascular disease and open a new avenue for the development of YAP/TAZ-targeting drugs to ameliorate progerin-induced atherosclerosis.